Jeffrey Pearl, MD
Urology · Mount Prospect, ILNPI 1437492360
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,369 of the $12,236 with a category attached, or 76.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations.
Across 395 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Intuitive Surgical$948
- Astellas Pharma US Inc$944
- Neotract Inc.$796
- Dendreon Pharmaceuticals LLC$787
- Johnson & Johnson$776
- plus $7K from 54 others
Across 38 payments — averaging $4089.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$66K
- Dendreon Pharmaceuticals LLC$47K
- AstraZeneca$33K
- Ortho-clinical Diagnostics, Inc.$9K
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$1,20010%
- Travel & lodging$1,24110%
- Food & beverage$9,36977%
- Education$1261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALZENNA$950
- Da Vinci Surgical System$850
- UroLift$600
- Erleada$300
- AquaBeam Robotic System$299
- UroLift System$156
- AKEEGA$150
- iTIND System$129
- PROVENGE$117
How this compares
$12,236 in reported general payments places this provider in the 85th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 53 | $722,595 |
| ErleadaApalutamide | 12 | $161,184 |
| OrgovyxRelugolix | 41 | $108,914 |
| GemtesaVibegron | 68 | $63,587 |
| MyrbetriqMirabegron | 28 | $27,760 |
| Tamsulosin Hcl | 663 | $9,523 |
| Finasteride | 464 | $6,911 |
| Testosterone | 26 | $3,911 |
| Potassium Citrate ErPotassium Citrate | 19 | $2,449 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 63 | $1,506 |
| Methenamine Hippurate | 21 | $1,304 |
| Testosterone Cypionate | 42 | $1,200 |
| Estradiol | 23 | $1,087 |
| Solifenacin Succinate | 12 | $758 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 21 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $944 | $750,35581 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $359 | $172,501109 claims |
| Johnson & JohnsonErleada | $776 | $161,18412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 550 urology providers in Illinois.
Other urology in Mount Prospect
- Scott TiplitskyMount Prospect$58K
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.